These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36158680)

  • 1. A comparison of four technologies for detecting p53 aggregates in ovarian cancer.
    Heinzl N; Koziel K; Maritschnegg E; Berger A; Pechriggl E; Fiegl H; Zeimet AG; Marth C; Zeillinger R; Concin N
    Front Oncol; 2022; 12():976725. PubMed ID: 36158680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloid-like p53 as prognostic biomarker in serous ovarian cancer-a study of the OVCAD consortium.
    Heinzl N; Maritschnegg E; Koziel K; Schilhart-Wallisch C; Heinze G; Yang WL; Bast RC; Sehouli J; Braicu EI; Vergote I; Van Gorp T; Mahner S; Paspalj V; Grimm C; Obermayr E; Schuster E; Holzer B; Rousseau F; Schymkowitz J; Concin N; Zeillinger R
    Oncogene; 2023 Aug; 42(33):2473-2484. PubMed ID: 37402882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymer-Ligand-Based ELISA for Robust, High-Throughput, Quantitative Detection of p53 Aggregates.
    Maritschnegg E; Heinzl N; Wilson S; Deycmar S; Niebuhr M; Klameth L; Holzer B; Koziel K; Concin N; Zeillinger R
    Anal Chem; 2018 Nov; 90(22):13273-13279. PubMed ID: 30277755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Application of PLA Method for Detection of p53/p63/p73 Complexes in Situ in Tumour Cells and Tumour Tissue].
    Hrabal V; Nekulová M; Nenutil R; Holčaková J; Coates PJ; Vojtěšek B
    Klin Onkol; 2017; 30(Supplementum1):159-162. PubMed ID: 28471195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer.
    Silva JL; Cino EA; Soares IN; Ferreira VF; A P de Oliveira G
    Acc Chem Res; 2018 Jan; 51(1):181-190. PubMed ID: 29260852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of the p53 transactivation domain results in high amyloid aggregation of the Δ40p53 isoform in endometrial carcinoma cells.
    Melo Dos Santos N; de Oliveira GAP; Ramos Rocha M; Pedrote MM; Diniz da Silva Ferretti G; Pereira Rangel L; Morgado-Diaz JA; Silva JL; Rodrigues Pereira Gimba E
    J Biol Chem; 2019 Jun; 294(24):9430-9439. PubMed ID: 31028175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitive detection of Aβ protofibrils by proximity ligation--relevance for Alzheimer's disease.
    Kamali-Moghaddam M; Pettersson FE; Wu D; Englund H; Darmanis S; Lord A; Tavoosidana G; Sehlin D; Gustafsdottir S; Nilsson LN; Lannfelt L; Landegren U
    BMC Neurosci; 2010 Oct; 11():124. PubMed ID: 20923550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-localization of mutant p53 and amyloid-like protein aggregates in breast tumors.
    Levy CB; Stumbo AC; Ano Bom AP; Portari EA; Cordeiro Y; Silva JL; De Moura-Gallo CV
    Int J Biochem Cell Biol; 2011 Jan; 43(1):60-4. PubMed ID: 21056685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytoplasmic p53 aggregates accumulated in p53-mutated cancer correlate with poor prognosis.
    Iwahashi N; Ikezaki M; Komohara Y; Fujiwara Y; Noguchi T; Nishioka K; Sakai K; Nishio K; Ueda M; Ihara Y; Uchimura K; Ino K; Nishitsuji K
    PNAS Nexus; 2022 Jul; 1(3):pgac128. PubMed ID: 36741442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells.
    Rangel LP; Ferretti GDS; Costa CL; Andrade SMMV; Carvalho RS; Costa DCF; Silva JL
    J Biol Chem; 2019 Mar; 294(10):3670-3682. PubMed ID: 30602570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer.
    Ano Bom AP; Rangel LP; Costa DC; de Oliveira GA; Sanches D; Braga CA; Gava LM; Ramos CH; Cepeda AO; Stumbo AC; De Moura Gallo CV; Cordeiro Y; Silva JL
    J Biol Chem; 2012 Aug; 287(33):28152-62. PubMed ID: 22715097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression P53 protein and chromosome aberrations in benign tumors and ovarian carcinoma].
    Kamiński K; Putowski L; Oleszczuk J
    Ginekol Pol; 2003 Sep; 74(9):741-5. PubMed ID: 14674118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel method for the sensitive detection of mutant proteins using a covalent-bonding tube-based proximity ligation assay.
    Jiang X; Zhou L; Cheng J; Zhang H; Wang H; Chen Z; Shi F; Zhu C
    Anal Chim Acta; 2014 Sep; 841():17-23. PubMed ID: 25109857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 Aggregates penetrate cells and induce the co-aggregation of intracellular p53.
    Forget KJ; Tremblay G; Roucou X
    PLoS One; 2013; 8(7):e69242. PubMed ID: 23844254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relevance of Amorphous and Amyloid-Like Aggregates of the p53 Core Domain to Loss of its DNA-Binding Activity.
    Hibino E; Tenno T; Hiroaki H
    Front Mol Biosci; 2022; 9():869851. PubMed ID: 35558561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ELISA-PLA: A novel hybrid platform for the rapid, highly sensitive and specific quantification of proteins and post-translational modifications.
    Tong QH; Tao T; Xie LQ; Lu HJ
    Biosens Bioelectron; 2016 Jun; 80():385-391. PubMed ID: 26866564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The aggregation of mutant p53 produces prion-like properties in cancer.
    Rangel LP; Costa DC; Vieira TC; Silva JL
    Prion; 2014; 8(1):75-84. PubMed ID: 24509441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analytical Validation of AmpliChip p53 Research Test for Archival Human Ovarian FFPE Sections.
    Marton MJ; McNamara AR; Nikoloff DM; Nakao A; Cheng J
    PLoS One; 2015; 10(6):e0131497. PubMed ID: 26125596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The (1-63) region of the p53 transactivation domain aggregates in vitro into cytotoxic amyloid assemblies.
    Rigacci S; Bucciantini M; Relini A; Pesce A; Gliozzi A; Berti A; Stefani M
    Biophys J; 2008 May; 94(9):3635-46. PubMed ID: 18199664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LC-MS/MS-based targeted proteomics quantitatively detects the interaction between p53 and MDM2 in breast cancer.
    Zhang W; Zhong T; Chen Y
    J Proteomics; 2017 Jan; 152():172-180. PubMed ID: 27826076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.